Phase II study of tamoxifen in patients with advanced renal cell carcinoma.
Explore the source record for details and available documents.
Adenocarcinoma↗
Biomedical subjects
D Harris
Publications and source records attributed to D Harris.
Tamoxifen in refractory metastatic carcinoma of the prostate.
Thirty-one patients with advanced metastatic carcinoma of the prostate were treated with the antiestrogen tamoxifen. Of these patients, 29 were refractory to prior hormonal manipulation with estrogens and/or orchiectomy and five achieved an objective response (partial regression of stable disease using National Prostatic Cancer Project criteria). Median survival of the responders was significantly longer than that of the nonresponders (P < 0.05). Two additional patients who had not previously received hormonal therapy both responded, for an overall response rate of 23% (seven of 31 patients). Toxicity was minimal and no tumor flares were reported. These preliminary results support the further clinical trial of tamoxifen in advanced cancer of the prostate.
Adenocarcinoma↗
Osseointegrated implants for single-tooth replacement: progress report from a multicenter prospective study after 3 years.
After 3 years, 82 of the original 92 patients remain in this prospective multicenter study of single-tooth restorations supported by Brånemark implants. Since the 1-year follow-up, 6 more patients have been lost, but no additional implants have failed in those patients examined at the 3-year follow-up visit. After 1 year of function, 97.2% of the implants survived in 88 patients, and between the 1- and 3-year follow-up, 100% survived in 82 patients, giving a 3-year cumulative success rate of 97.2%. No changes were observed in the status of gingivitis, pocket depth, periodontal pocket bleeding index, and tooth and implant mobility from those reported after 1 year. Marginal bone resorption remained at a low level--less than 0.1 mm annually during the second and third years. Abutment screw loosening continued, but at a significantly reduced rate from that reported after 1 year. When used, gold rather than titanium abutment screws remained secure.
Adult↗
Osseointegrated implants for single-tooth replacement: a prospective 5-year multicenter study.
One hundred seven Brånemark implants were placed in 92 patients participating in an international multicenter trial on single-implant restorations at seven centers. The patients were followed for 5 years in a prospective study focusing on implant success and crown function. Plaque and gingival indexes, as well as probing depths, were recorded around teeth and implants. The marginal bone level at implants was determined from intraoral radiographs. Only three implants (2.8%) had been lost at the final annual checkup. During the follow-up period, a total of 17 patients dropped out or were excluded because of nonconformity with the protocol. Based on the remaining patients, a total of 86 implants were clinically and radiographically evaluated at the 5-year follow-up period, resulting in a cumulative success rate of 96.6% (71 implants) in the maxillae and 100% (15 implants) in the mandibles. Plaque and gingival indexes showed a similar pattern of good health around both natural teeth and titanium abutments. The marginal bone loss during the 5-year period did not exceed 1 mm as a mean for all implants analyzed. The most frequent complication recorded during the follow-up was loosening of the abutment fixation screw. The outcome of this study indicated that safe and highly predictable results can be obtained for 5 years when Brånemark implants are used to support single-tooth restorations.
Alveolar Bone Loss↗
High-throughput DNA sequencing on a capillary array electrophoresis system.
A capillary array electrophoresis apparatus capable of running and analyzing 48 DNA sequencing samples simultaneously has been constructed. The instrument uses a replaceable sieving buffer and incorporates a convenient method for introducing the buffer into the capillaries. Data from laser-induced fluorescence are collected as four separate images, one for each optical channel. The integrated data analysis software employs an open architecture that allows use of any DNA base-calling algorithm. DNA sequencing runs are completed in approx. 1 hr (approximately 500 bases), and instrument turnaround time between runs is less than 15 min. Overall, the instrument throughput is on the order of 720 templates/day, or 360,000 bases/day.
Animals↗